KR102098977B1 - 헤테로 방향환 메틸 환상 아민 유도체 - Google Patents
헤테로 방향환 메틸 환상 아민 유도체 Download PDFInfo
- Publication number
- KR102098977B1 KR102098977B1 KR1020147035124A KR20147035124A KR102098977B1 KR 102098977 B1 KR102098977 B1 KR 102098977B1 KR 1020147035124 A KR1020147035124 A KR 1020147035124A KR 20147035124 A KR20147035124 A KR 20147035124A KR 102098977 B1 KR102098977 B1 KR 102098977B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- methanone
- pyrazol
- phenyl
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XRHQUGWNTXYCGK-UHFFFAOYSA-N CC(C1)COC(CO)N1C(c(cc(C)cc1)c1-[n]1nccn1)=O Chemical compound CC(C1)COC(CO)N1C(c(cc(C)cc1)c1-[n]1nccn1)=O XRHQUGWNTXYCGK-UHFFFAOYSA-N 0.000 description 1
- MPEBTPDHFLWMMX-UHFFFAOYSA-N CC(C1)COC(C[n]2ncc(-c(cc3)ncc3F)c2)N1C(c1cc(C)ccc1-[n]1nccn1)=O Chemical compound CC(C1)COC(C[n]2ncc(-c(cc3)ncc3F)c2)N1C(c1cc(C)ccc1-[n]1nccn1)=O MPEBTPDHFLWMMX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012135277 | 2012-06-15 | ||
| JPJP-P-2012-135277 | 2012-06-15 | ||
| PCT/JP2013/066322 WO2013187467A1 (ja) | 2012-06-15 | 2013-06-13 | ヘテロ芳香環メチル環状アミン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150023391A KR20150023391A (ko) | 2015-03-05 |
| KR102098977B1 true KR102098977B1 (ko) | 2020-04-08 |
Family
ID=49758285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147035124A Active KR102098977B1 (ko) | 2012-06-15 | 2013-06-13 | 헤테로 방향환 메틸 환상 아민 유도체 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9266870B2 (enExample) |
| EP (1) | EP2862860B1 (enExample) |
| JP (1) | JP5896319B2 (enExample) |
| KR (1) | KR102098977B1 (enExample) |
| CN (1) | CN104350053B (enExample) |
| AU (1) | AU2013275210B2 (enExample) |
| BR (1) | BR112014031360B1 (enExample) |
| CA (1) | CA2876253C (enExample) |
| CY (1) | CY1118848T1 (enExample) |
| DK (1) | DK2862860T3 (enExample) |
| ES (1) | ES2613663T3 (enExample) |
| HR (1) | HRP20161797T1 (enExample) |
| HU (1) | HUE031538T2 (enExample) |
| IL (1) | IL236140A (enExample) |
| IN (1) | IN2014DN10490A (enExample) |
| LT (1) | LT2862860T (enExample) |
| ME (1) | ME02606B (enExample) |
| MX (1) | MX355660B (enExample) |
| MY (1) | MY171464A (enExample) |
| NZ (1) | NZ702647A (enExample) |
| PH (1) | PH12014502750B1 (enExample) |
| PL (1) | PL2862860T3 (enExample) |
| PT (1) | PT2862860T (enExample) |
| RS (1) | RS55675B1 (enExample) |
| RU (1) | RU2639869C2 (enExample) |
| SG (1) | SG11201408327XA (enExample) |
| SI (1) | SI2862860T1 (enExample) |
| SM (1) | SMT201700141T1 (enExample) |
| TW (1) | TWI583683B (enExample) |
| WO (1) | WO2013187467A1 (enExample) |
| ZA (1) | ZA201409168B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2585806T3 (es) | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
| CN105814042B (zh) * | 2013-12-13 | 2018-09-28 | 大正制药株式会社 | 噁嗪烷化合物的晶形及其制造方法 |
| CN104370755B (zh) * | 2014-08-18 | 2017-04-12 | 江西隆莱生物制药有限公司 | 一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法 |
| JP2018188364A (ja) * | 2015-10-02 | 2018-11-29 | 大正製薬株式会社 | 複素芳香環誘導体 |
| HRP20220642T1 (hr) | 2016-03-10 | 2022-06-24 | Janssen Pharmaceutica Nv | Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 |
| CN108129426B (zh) * | 2016-12-01 | 2021-06-29 | 中国科学院大连化学物理研究所 | 一种2,5-二氰基呋喃催化加氢合成2,5-二甲胺基呋喃的方法 |
| JOP20190156B1 (ar) * | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
| WO2019013244A1 (ja) | 2017-07-13 | 2019-01-17 | 大正製薬株式会社 | （２ｓ）－２－［（１ｈ－ピラゾール－１－イル）メチル］－１，３－オキサジナン誘導体の製造方法 |
| CN110967321A (zh) * | 2018-09-29 | 2020-04-07 | 泰州医药城国科化物生物医药科技有限公司 | 一种用于均一体系细胞荧光检测钙流方法 |
| US20230310652A1 (en) | 2020-05-22 | 2023-10-05 | Neuway Pharma Gmbh | Vlp for the treatment of leukodystrophies |
| CN113336655A (zh) * | 2020-12-30 | 2021-09-03 | 江西迪赛诺制药有限公司 | 一种(r)-3-氨基丁醇的制备方法 |
| CN116925022B (zh) * | 2023-07-06 | 2025-08-01 | 江苏信和生物医药有限公司 | 一种(s)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008062878A1 (fr) | 2006-11-22 | 2008-05-29 | Nihon Nohyaku Co., Ltd. | Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles |
| JP2012507539A (ja) | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト |
| JP2012507538A (ja) | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | イソニコチンアミドオレキシン受容体アンタゴニスト |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| US7169744B2 (en) * | 2002-06-06 | 2007-01-30 | Procter & Gamble Company | Organic catalyst with enhanced solubility |
| EP2131654A4 (en) | 2007-03-02 | 2011-02-02 | Merck Sharp & Dohme | Bipyridine-carboxamide-orexin receptor Antagonist |
| WO2008147518A1 (en) * | 2007-05-23 | 2008-12-04 | Merck & Co., Inc. | Pyridyl piperidine orexin receptor antagonists |
| CA2695621A1 (en) * | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
| WO2010038200A1 (en) * | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| WO2010044054A1 (en) | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| AU2009307916A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| US20130281465A1 (en) | 2010-12-17 | 2013-10-24 | Taisho Pharmaceutical Co., Ltd. | Pyrazole derivative |
| EP2708537A4 (en) | 2011-05-10 | 2014-10-01 | Taisho Pharmaceutical Co Ltd | HETEROAROMATIC RING DERIVATIVE |
-
2013
- 2013-06-13 IN IN10490DEN2014 patent/IN2014DN10490A/en unknown
- 2013-06-13 SG SG11201408327XA patent/SG11201408327XA/en unknown
- 2013-06-13 LT LTEP13804876.4T patent/LT2862860T/lt unknown
- 2013-06-13 CN CN201380031372.4A patent/CN104350053B/zh active Active
- 2013-06-13 HU HUE13804876A patent/HUE031538T2/en unknown
- 2013-06-13 SI SI201330457A patent/SI2862860T1/sl unknown
- 2013-06-13 WO PCT/JP2013/066322 patent/WO2013187467A1/ja not_active Ceased
- 2013-06-13 PL PL13804876T patent/PL2862860T3/pl unknown
- 2013-06-13 BR BR112014031360-1A patent/BR112014031360B1/pt active IP Right Grant
- 2013-06-13 US US14/407,353 patent/US9266870B2/en active Active
- 2013-06-13 HR HRP20161797TT patent/HRP20161797T1/hr unknown
- 2013-06-13 SM SM20170141T patent/SMT201700141T1/it unknown
- 2013-06-13 ME MEP-2017-34A patent/ME02606B/me unknown
- 2013-06-13 MX MX2014015077A patent/MX355660B/es active IP Right Grant
- 2013-06-13 CA CA2876253A patent/CA2876253C/en active Active
- 2013-06-13 RU RU2015101102A patent/RU2639869C2/ru active
- 2013-06-13 DK DK13804876.4T patent/DK2862860T3/en active
- 2013-06-13 ES ES13804876.4T patent/ES2613663T3/es active Active
- 2013-06-13 JP JP2014521401A patent/JP5896319B2/ja active Active
- 2013-06-13 MY MYPI2014703693A patent/MY171464A/en unknown
- 2013-06-13 PT PT138048764T patent/PT2862860T/pt unknown
- 2013-06-13 NZ NZ702647A patent/NZ702647A/en unknown
- 2013-06-13 AU AU2013275210A patent/AU2013275210B2/en active Active
- 2013-06-13 EP EP13804876.4A patent/EP2862860B1/en active Active
- 2013-06-13 KR KR1020147035124A patent/KR102098977B1/ko active Active
- 2013-06-13 RS RS20170123A patent/RS55675B1/sr unknown
- 2013-06-14 TW TW102121127A patent/TWI583683B/zh active
-
2014
- 2014-12-08 IL IL236140A patent/IL236140A/en active IP Right Grant
- 2014-12-09 PH PH12014502750A patent/PH12014502750B1/en unknown
- 2014-12-12 ZA ZA2014/09168A patent/ZA201409168B/en unknown
-
2017
- 2017-03-08 CY CY20171100300T patent/CY1118848T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008062878A1 (fr) | 2006-11-22 | 2008-05-29 | Nihon Nohyaku Co., Ltd. | Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles |
| JP2012507539A (ja) | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト |
| JP2012507538A (ja) | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | イソニコチンアミドオレキシン受容体アンタゴニスト |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5896319B2 (ja) | ヘテロ芳香環メチル環状アミン誘導体 | |
| US11759462B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
| EA035544B1 (ru) | Производные тетрагидроизохинолина | |
| JPWO2013187466A1 (ja) | 分岐鎖アルキルヘテロ芳香環誘導体 | |
| WO2013005755A1 (ja) | メチルピペリジン誘導体 | |
| US11548882B2 (en) | Benzisoxazole compound | |
| WO2012153729A1 (ja) | ヘテロ芳香環誘導体 | |
| JP5930010B2 (ja) | ヘテロ芳香環メチル環状アミン誘導体を含有する医薬 | |
| WO2018202694A1 (en) | Heterocyclic p2x7 antagonists | |
| JP2014141480A (ja) | メチルピペリジン誘導体を含有する医薬 | |
| JP2015131802A (ja) | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 | |
| TW201609718A (zh) | 唑啶以及噁嗪烷衍生物 | |
| WO2017057717A1 (ja) | 複素芳香環誘導体 | |
| HK1202540B (en) | Heteroaromatic methyl cyclic amine derivative | |
| HK1188447A (en) | Pyrazole derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20141215 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180529 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190722 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200129 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200402 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200402 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |